Hormonal ablation as effective therapy for carcinomatous meningitis from prostatic carcinoma. uri icon

Overview

abstract

  • BACKGROUND: Metastases to the meninges from prostatic cancer are rare, accounting for less than 0.5% of all solid tumor cases. Management for patients with leptomeningeal metastases of various histologic types includes intrathecal chemotherapy and radiation therapy, but the prognosis is poor. Therefore, the identification of selected patients for whom effective therapy exists is of paramount importance. METHODS: A patient with adenocarcinoma of the prostate presented with leptomeningeal metastases as his first manifestation of metastatic disease. RESULTS: Androgen blockade was initiated with flutamide and ketoconazole. After 5 days of therapy, leuprolide acetate depot was substituted for ketoconazole. The patient responded to therapy and remained asymptomatic with a normal serum prostate-specific antigen levels at 16-plus months with no further evidence of malignant cells in spinal fluid from repeated lumbar punctures. CONCLUSION: Patients with hormone-naive metastatic prostatic carcinoma manifested as carcinomatous meningitis should be considered for hormonal ablative therapy. This is preferred to the use of intrathecal chemotherapy, which has limited efficacy.

publication date

  • April 1, 1994

Research

keywords

  • Adenocarcinoma
  • Androgen Antagonists
  • Antineoplastic Combined Chemotherapy Protocols
  • Flutamide
  • Ketoconazole
  • Meningeal Neoplasms
  • Meningitis
  • Prostatic Neoplasms

Identity

Scopus Document Identifier

  • 0028314363

Digital Object Identifier (DOI)

  • 10.1002/1097-0142(19940401)73:7<1892::aid-cncr2820730720>3.0.co;2-c

PubMed ID

  • 8137217

Additional Document Info

volume

  • 73

issue

  • 7